The following commitment statement was released by the White House in a Fact Sheet on June 29, and highlighted by Vice President Joe Biden in his introductory comments:
“The Moonshot cannot be achieved by one person, one organization, one discipline, or even one collective approach,” said Vice President Biden. “Solving the complexities of cancer will require the formation of new alliances to defy the bounds of innovation and accelerate the prevention, diagnosis, treatment, and — ultimately — a cure. It’s going to require millions of Americans speaking up and contributing what they’re able. That’s what the Cancer Moonshot Summit is all about.”
Several representatives of OPeN participated in the Cancer Moonshot Summit. Representatives included Lincoln Nadauld, MD, PhD, executive director of Precision Medicine and Precision Genomics at Intermountain Healthcare, Thomas Brown, MD, executive director of the Swedish Cancer Institute and co-chair of Providence Health & Services’ Personalized Medicine Program, Leroy Hood, MD, senior vice president and chief scientific officer for Providence Health & Services, James Ford, MD, director of Clinical Cancer Genomics at the Stanford Cancer Institute, and Jonathan Hirsch, founder and president of Syapse.
Members of the network already have a strong voice in the Cancer Moonshot conversation, making this collaboration a force in cancer treatment development and access. In June, the White House Cancer Moonshot team published a blog post by Jonathan Hirsch about the need for data sharing and the launch of OPeN: http://bit.ly/292Xc2p.
In February, Dr. Nadauld and Mr. Hirsch participated in the White House Precision Medicine Initiative Summit hosted by President Barack Obama. Also in February, Intermountain’s president and CEO, Dr. Charles Sorenson, and Dr. Raj Srivastava, Intermountain’s Research medical director, met with Vice President Joe Biden and other local medical leaders in Salt Lake City to discuss cancer research and treatment. Drs. Brown and Hood participated in a discussion of cancer treatment programs with the vice president during a visit to Seattle.
Intermountain Healthcare, Stanford Cancer Institute, Providence Health & Services, and Syapse joined together earlier this June to announce the formation of OPeN. Details of that announcement are available at https://intermountainhealthcare.org/news/2016/06/pioneering-data-sharing-network-created/.
About Intermountain Healthcare
Intermountain Healthcare is a Utah-based, not-for-profit system of 22 hospitals, 185 clinics, a Medical Group with over 1,400 employed physicians and advanced practice clinicians, a health plans division called SelectHealth, and other health services. Helping people live the healthiest lives possible®, Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs.
About Providence Health & Services
Providence Health & Services is a not-for-profit Catholic health care ministry committed to providing for the needs of the communities it serves – especially for those who are poor and vulnerable. Providence's services include 34 hospitals, 600 physician clinics, senior services, supportive housing and many other health and educational services. The health system and its affiliates employ more than 82,000 people across five states – Alaska, California, Montana, Oregon and Washington – with its system office located in Renton, Washington. In 2015, Through its cancer institute model, Providence is dedicated to national leadership in personalized medicine and innovative research, delivering the best treatments to patients close to home and, when necessary, connecting patients to world-class physicians and caregivers across our network.
About Stanford Cancer Institute (SCI)
Stanford Cancer Institute is a National Cancer Institute-designated Cancer Center dedicated and resourced to catalyze the vast scientific, technological and human capabilities of Stanford University and Stanford Medicine to advance understanding of cancer and rapidly translate research discoveries into improved prevention strategies, diagnostics and therapies.
Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models. Syapse Precision Medicine Platform is a comprehensive software suite used by leading health systems to support the clinical implementation of precision medicine in oncology and other service lines. This category-defining platform enables clinical and genomic data integration, decision support, care coordination, and quality improvement at point of care. Headquartered in Palo Alto, California, with offices in Philadelphia, Pennsylvania, Syapse is backed by Ascension Ventures, Safeguard Scientifics (NYSE:SFE), and Social Capital.